ASTRAZEN.NS Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (29 apr 2024 @ 11:59):

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally...

Stats
Dagens volum	17 271.00
Gjennomsnittsvolum	20 660.00
Markedsverdi	138.87B
EPS	INR0 ( 2024-02-08 )
Neste inntjeningsdato	( INR0 ) 2024-05-28
Last Dividend	INR16.00 ( 2023-07-14 )
Next Dividend	INR0 ( N/A )
P/E	99.39
ATR14	INR7.70 (0.14%)

Volum Korrelasjon

Lang: -0.03 (neutral)

Kort: -0.19 (neutral)

Signal:(59.051) Neutral

AstraZeneca Pharma India Korrelasjon

10 Mest positive korrelasjoner
SEYAIND.NS	0.834

10 Mest negative korrelasjoner
CONTROLPR.NS	-0.807

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

AstraZeneca Pharma India Korrelasjon - Valuta/Råvare

-0.30
( neutral )

-0.24
( neutral )

-0.15
( neutral )

0.07
( neutral )

0.64
( weak )

-0.31
( neutral )

AstraZeneca Pharma India Økonomi

Annual	2022
Omsetning:	INR10.03B
Bruttogevinst:	INR5.45B (54.37 %)
EPS:	INR39.72

FY	2022
Omsetning:	INR10.03B
Bruttogevinst:	INR5.45B (54.37 %)
EPS:	INR39.72

FY	2022
Omsetning:	INR8.06B
Bruttogevinst:	INR4.48B (55.63 %)
EPS:	INR24.60

FY	2021
Omsetning:	INR8.09B
Bruttogevinst:	INR4.78B (59.12 %)
EPS:	INR37.30

Financial Reports:

No articles found.

AstraZeneca Pharma India Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
INR8.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR16.00 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)	INR0 (N/A)

AstraZeneca Pharma India Dividend Information - Dividend Junior

Dividend Sustainability Score: 4.66 - low (54.78%) | Divividend Growth Potential Score: 2.22 - Decrease likely (55.55%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information

First Dividend	INR3.70	2003-04-17
Last Dividend	INR16.00	2023-07-14
Next Dividend	INR0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	16	--
Total Paid Out	INR184.10	--
Avg. Dividend % Per Year	0.19%	--
Score	1.47	--
Div. Sustainability Score	4.66
Div.Growth Potential Score	2.22
Div. Directional Score	3.44	--

Next Divdend (Est)
(2024-09-25)

INR18.37 Estimate 2.96 %

Dividend Stability

0.24 Very Poor

Dividend Score

1.47

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2003	INR0	0.00%
2004	INR0	0.00%
2005	INR0	0.00%
2006	INR0	0.00%
2007	INR0	0.00%
2008	INR0	0.00%
2009	INR0	0.00%
2010	INR0	0.00%
2011	INR0	0.00%
2012	INR0	0.00%
2013	INR0	0.00%
2014	INR0	0.00%
2015	INR0	0.00%
2016	INR0	0.00%
2017	INR0	0.00%
2018	INR0	0.00%
2019	INR1.000	0.07%
2020	INR2.00	0.08%
2021	INR2.00	0.04%
2022	INR8.00	0.26%
2023	INR16.00	0.48%
2024	INR0	0.00%

Dividend Commentary

The company's low Dividend Sustainability Score (DSS) highlights potential challenges in upholding its current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In conclusion, a more vigilant stance is recommended given the company's tentative dividend landscape.

Top 10 dividend Companies for NSE

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend
SANDHAR.NS	Dividend Junior	2023-09-14	Annually	7	0.66%
LXCHEM.NS	Dividend Junior	2023-07-20	Annually	4	0.11%
GLENMARK.NS	Dividend Junior	2023-09-18	Annually	23	0.37%
ASIANPAINT.NS	Dividend Junior	2023-06-09	Semi-Annually	23	0.43%
TINPLATE.NS	Dividend Junior	2023-08-11	Annually	19	0.72%
PDMJEPAPER.NS	Dividend Junior	2023-08-03	Annually	9	0.65%
J&KBANK.NS	Dividend Junior	2023-08-17	Sporadic	22	0.47%
DATAMATICS.NS	Dividend Junior	2023-09-22	Annually	21	0.49%
SHYAMMETL.NS	Dividend Junior	2023-06-05	Semi-Annually	4	0.70%
MAXHEALTH.NS	Dividend Junior	2023-09-08	Insufficient data to determine frequency	2	0.07%

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.116	1.500	7.67	10.00	[0 - 0.5]
returnOnAssetsTTM	0	1.200	0	0	[0 - 0.3]
returnOnEquityTTM	0.224	1.500	8.62	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	0	0.800	-5.00	-4.00	[1 - 3]
quickRatioTTM	0	0.800	-4.71	-3.76	[0.8 - 2.5]
cashRatioTTM	0	1.500	-1.111	-1.667	[0.2 - 2]
debtRatioTTM	0	-1.500	0	0	[0 - 0.6]
interestCoverageTTM	128.03	1.000	10.00	10.00	[3 - 30]
operatingCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
freeCashFlowPerShareTTM	9.89	2.00	5.06	10.00	[0 - 20]
debtEquityRatioTTM	0	-1.500	0	0	[0 - 2.5]
grossProfitMarginTTM	0.518	1.000	4.71	4.71	[0.2 - 0.8]
operatingProfitMarginTTM	0.145	1.000	9.10	9.10	[0.1 - 0.6]
cashFlowToDebtRatioTTM	0	1.000	-1.111	-1.111	[0.2 - 2]
assetTurnoverTTM	0	0.800	-3.33	-2.67	[0.5 - 2]
Total Score				4.66

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	97.68	1.000	0.235	0	[1 - 100]
returnOnEquityTTM	0.224	2.50	9.11	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
dividendYielPercentageTTM	0.294	1.500	2.65	0	[0 - 0.4]
operatingCashFlowPerShareTTM	9.89	2.00	6.70	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	-2.87	1.500	-10.00	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.0207	1.000	-1.984	0	[0.1 - 0.5]
Total Score				2.22

AstraZeneca Pharma India

AstraZeneca Pharma India Limited, a biopharmaceutical company, manufactures, distributes, and markets pharmaceutical products in India and internationally. It manufactures and sells cardiovascular disease and diabetes medicines under the Brilinta, Betaloc, Crestor, Forxiga, Imdur, Kombiglyze XR, Onglyza, Seloken XL, Xigduo XR, and QTERN brands; Respiratory medicines under the Symbicort and FASENRA brand names; and oncology medicines under the LYNPARZA, Tagrisso, Iressa, Calquence, Casodex, Faslodex, Zoladex, and Arimidex brands. The company also offers products in the areas of renal, metabolic, and immunology diseases. It also provides clinical trial services. The company was incorporated in 1979 and is based in Bengaluru, India. AstraZeneca Pharma India Limited is a subsidiary of AstraZeneca Pharmaceuticals AB.